MIR in atypical idiopathic inflammatory demyelinating disease treated with methylprednisolone and cyclophosphamide.
Kallweit
U
U
Department of Neurology, Kamillus-Klinik, Asbach, Germany.
Pöhlau
D
D
Pauleit
D
D
Harzheim
M
M
D000293:Adolescent; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000627:therapeutic use*; D005260:Female; D020275:Guillain-Barre Syndrome / Q000175:diagnosis* / Q000188:drug therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008279:Magnetic Resonance Imaging / Q000379:methods*; D008775:Methylprednisolone / Q000627:therapeutic use*
D000893:Anti-Inflammatory Agents; D007166:Immunosuppressive Agents; D003520:Cyclophosphamide; D008775:Methylprednisolone